CSMD2

Across TCGA pan-cancer cohorts, CSMD2 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated CSMD2 data layer compared with 6 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher CSMD2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CSMD2 expression acts as an unfavorable survival marker, although some lineages such as ACC and CHOL show a favorable association.

KIRP, UVM, and LIHC are the cancer types where CSMD2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.494	0.774	<.001	89	view →
UVM	DFS	Tertile	All	0.320	0.687	.002	48	view →
LIHC	OS	Tertile	All	0.699	0.863	<.001	37	view →
BLCA	DFS	Median	All	0.453	0.567	.010	34	view →
ACC	OS	Median	III,IV	0.854	0.613	.016	34	view →
BRCA	OS	Median	III,IV	0.777	0.882	.009	30	view →
STAD	OS	Median	All	0.511	0.651	.003	29	view →
CHOL	DFS	Median	IV	0.858	0.339	.017	27	view →
KIRC	OS	Median	All	0.847	0.771	.022	14	view →
SKCM	DFS	Tertile	IV	0.765	0.245	.012	12	view →
THYM	OS	Tertile	All	0.919	1.000	.010	11	view →
CESC	DFS	Median	All	0.778	0.859	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

CSMD2–KIRP (OS)

Open the KIRP breakdown →